|
FY2026
12 months to Apr 30, 2026
|
FY2025
12 months to Apr 30, 2025
|
FY2024
12 months to Apr 30, 2024
|
FY2023
12 months to Apr 30, 2023
|
FY2022
12 months to Apr 30, 2022
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Operating expenses: | |||||
| Research and development costs | |||||
| Compensation expense | |||||
| Director fees | |||||
| Legal and professional | |||||
| Intangible asset impairment | |||||
| General and administrative | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Interest income | |||||
| Dividend income | |||||
| Change in fair value of warrant liability | |||||
| Change in fair value of derivative liability | |||||
| Change in fair value of convertible note receivable – Femasys | |||||
| Change in fair value of warrant asset | |||||
| Change in fair value of investment | |||||
| Change in fair value of warrants | |||||
| Gain on investment in preferred stock – TNF | |||||
| Change in fair value of investment – QCLS | |||||
| Change in fair value of warrant assets – QCLS | |||||
| Gain on related party investment – QCLS | |||||
| Gain on legal settlement – re-fair value of warrants | |||||
| Issuance costs – Series C convertible preferred stock and warrants | |||||
| Unrealized gain (loss) on marketable securities | |||||
| Loss on legal settlement | |||||
| Loss on long term asset | |||||
| Loss on issuance of Series C preferred stock | |||||
| Other expense, net | |||||
| Total other income (expense), net | |||||
| Income tax benefit (expense) | |||||
| Net income (loss) | |||||
| Preferred stock dividends | |||||
| Undistributed income to Series B convertible preferred stock | |||||
| Preferred stock accretion | |||||
| Net income (loss) attributable to common stockholders | |||||
| Basic income (loss) per share attributable to common stockholders | |||||
| Diluted income (loss) per share attributable to common stockholders | |||||
| Weighted average shares outstanding basic | |||||
| Weighted average shares outstanding diluted | |||||
Loading...
